Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation (SIA-CSH)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03965429|
Recruitment Status : Recruiting
First Posted : May 29, 2019
Last Update Posted : May 29, 2019
|Condition or disease||Intervention/treatment|
|Malignant Hemopathy||Other: Blood samples (additional tubes from care) longitudinal Other: Blood samples (additional tubes from care) at inclusion|
|Study Type :||Observational|
|Estimated Enrollment :||1020 participants|
|Official Title:||Immunological Follow-up After Allogeneic Hematopoietic Stem Cell Transplantation|
|Actual Study Start Date :||May 14, 2019|
|Estimated Primary Completion Date :||May 14, 2029|
|Estimated Study Completion Date :||May 31, 2029|
In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor.
Other: Blood samples (additional tubes from care) at inclusion
In the case of a transplant from an intrafamily donor (genoid or haploid), we will also collect blood samples from the donor. A single blood sample of 28 mL (7 EDTA tubes) will be made.
In order not to represent an additional sample for the donor, this sample will be taken before the mobilization of the hematopoietic stem cells, during the biological assessment required for the biological donation qualification.
Systematic longitudinal collection of blood samples for any patient receiving an allogeneic CSH transplant in our facility, regardless of donor category selected and type of graft used
Other: Blood samples (additional tubes from care) longitudinal
Some sampling times will be systematic, while others will only be performed in the presence of specific post-transplant clinical events (eg relapse, GVH ...).
- Evolution of the immune blood populations in patients who have received allogeneic hematopoietic stem cell transplantation. [ Time Frame: 5 years after HSC transplantation ]longitudinal study of the immune subpopulations of allografted patients for hematological malignancies.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03965429
|Contact: Dominique Genre, MDemail@example.com|
|Contact: Margot Berline, MSc, MBAfirstname.lastname@example.org|
|Marseille, Bouches-du Rhône, France, 13009|
|Contact: Dominique GENRE, MD +33 4 91 22 37 78 email@example.com|
|Principal Investigator: Raynier DEVILLIER|
|Principal Investigator:||Raynier Devillier, MD, PhD||Institut Paoli-Calmettes|